Genetic associations of the visfatin G-948T polymorphism with obesity-related metabolic traits in an Iranian population

被引:6
作者
Javanmard, Shaghayegh Haghjooy [1 ]
Dehghananzadeh, Raheleh [1 ]
Rafiee, Laleh [1 ]
Naji, Hajar [1 ]
Rezayat, Azadeh [1 ]
Sarrafzadegan, Nizal [2 ]
机构
[1] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Appl Physiol Res Ctr, Hezarjerib St, Esfahan, Iran
[2] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Isfahan Cardiovasc Res Ctr, Esfahan, Iran
来源
JOURNAL OF RESEARCH IN MEDICAL SCIENCES | 2016年 / 21卷
关键词
G-948T; Iran; lipoprotein; obesity; polymorphism; visfatin; TYPE-2; DIABETES-MELLITUS; COLONY-ENHANCING FACTOR; PLASMA VISFATIN; FAT; INFLAMMATION; CHOLESTEROL; PBEF1; RISK;
D O I
10.4103/1735-1995.193177
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Obesity is a global public health problem. Visfatin, as an adipocytokine, is coded by a gene known as nicotinamide phosphoribosyltransferase. So far, results were conflicted regarding correlations of visfatin with obesity and metabolic variables. he present study aimed to explore the association between G-948T polymorphism of visfatin gene with obesity and lipid profile in a nationally representative sample of Iranian population. Materials and Methods: In this case-control study, we assessed 129 randomly selected patients with obesity and 182 healthy normal weight controls from participants of Isfahan Healthy Heart Program. Genomic DNA was isolated from peripheral blood cells, and high-resolution melt polymerase chain reaction was performed to explore the presence of G-948T polymorphism. Results: T carriers "GT + TT" were statistically more frequent in the obese patients than the controls (P = 0.013; odds ratio = 1.9, 95% confidence interval = 1.1-3.1). he serum levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) were significantly different between T carriers and GG homozygote genotype (P = 0.03 and 0.02, respectively). Conclusion: We concluded that visfatin G-948T polymorphism was correlated with obesity, total cholesterol, and LDL-C levels in our population.
引用
收藏
页数:5
相关论文
共 30 条
[1]   The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity [J].
Belo, V. A. ;
Luizon, M. R. ;
Lacchini, R. ;
Miranda, J. A. ;
Lanna, C. M. M. ;
Souza-Costa, D. C. ;
Tanus-Santos, J. E. .
INTERNATIONAL JOURNAL OF OBESITY, 2015, 39 (01) :130-135
[2]   Plasma visfatin concentrations and fat depot-specific mRNA expression in humans [J].
Berndt, J ;
Klöting, N ;
Kralisch, S ;
Kovacs, P ;
Fasshauer, M ;
Schön, MR ;
Stumvoll, M ;
Blüher, M .
DIABETES, 2005, 54 (10) :2911-2916
[3]   Nicotinamide Phosphoribosyltransferase/Pre-B-Cell Colony Enhancing Factor/Visfatin Plasma Levels and Clinical Outcome in Patients With Dilated Cardiomyopathy [J].
Bobbert, Peter ;
Kuehl, Uwe ;
Poller, Wolfgang ;
Rauch, Ursula ;
Schultheiss, Heinz-Peter ;
Skurk, Carsten .
JOURNAL OF CARDIAC FAILURE, 2015, 21 (04) :330-338
[4]   Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans [J].
Boettcher, Yvonne ;
Teupser, Daniel ;
Enigk, Beate ;
Berndt, Janin ;
Kloeting, Nora ;
Schoen, Michael R. ;
Thiery, Joachim ;
Blueher, Matthias ;
Stumvoll, Michael ;
Kovacs, Peter .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07) :2725-2731
[5]   The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids [J].
Chang, Yi-Cheng ;
Chang, Tien-Jyun ;
Lee, Wei-Jei ;
Chuang, Lee-Ming .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2010, 59 (01) :93-99
[6]   Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus [J].
Chen, MP ;
Chung, FM ;
Chang, DM ;
Tsai, JCR ;
Huang, HF ;
Shin, SJ ;
Lee, YJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :295-299
[7]   Macrophages in human visceral adipose tissue:: increased accumulation in obesity and a source of resistin and visfatin [J].
Curat, CA ;
Wegner, V ;
Sengenès, C ;
Miranville, A ;
Tonus, C ;
Busse, R ;
Bouloumié, A .
DIABETOLOGIA, 2006, 49 (04) :744-747
[8]   Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance [J].
Dogru, Teoman ;
Sonmez, Alper ;
Tasci, Ilker ;
Bozoglu, Ergun ;
Yilmaz, Mahmut Ilker ;
Genc, Halil ;
Erdem, Gokhan ;
Gok, Mahmut ;
Bingol, Necati ;
Kilic, Selim ;
Ozgurtas, Taner ;
Bingol, Sezin .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (01) :24-29
[9]   Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity [J].
Esteghamati, Alireza ;
Alamdari, Azam ;
Zandieh, Ali ;
Elahi, Seerat ;
Khalilzadeh, Omid ;
Nakhjavani, Manouchehr ;
Meysamie, Alipasha .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 91 (02) :154-158
[10]   RETRACTED: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin (Retracted article, see vol 318, pg 565, 2007) [J].
Fukuhara, A ;
Matsuda, M ;
Nishizawa, M ;
Segawa, K ;
Tanaka, M ;
Kishimoto, K ;
Matsuki, Y ;
Murakami, M ;
Ichisaka, T ;
Murakami, H ;
Watanabe, E ;
Takagi, T ;
Akiyoshi, M ;
Ohtsubo, T ;
Kihara, S ;
Yamashita, S ;
Makishima, M ;
Funahashi, T ;
Yamanaka, S ;
Hiramatsu, R ;
Matsuzawa, Y ;
Shimomura, I .
SCIENCE, 2005, 307 (5708) :426-430